Needham Reiterates Buy Rating on Medtronic plc
Needham maintains a buy rating for Medtronic with a $101 price target, a 27.41% upside from the current price.
Key Points
- Needham reiterated its buy rating for Medtronic plc with a price target of $101 on June 17, 2026.
- Needham's $101 price target implies 27.41% upside from Medtronic plc's ($MDT) current $79.27 share price.
- Medtronic shares are trading at $80.38, with a market cap of $104.4 billion and a P/E ratio of 21.57.
- Insider transactions include sales by executives like CEO Geoffrey Martha and EVP Harry Skip Kiil in early June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Needham reiterated its buy rating on Medtronic plc (NYSE:MDT), setting a price target of $101. The analyst, Mike Matson, suggests a positive outlook for the medical device company as its shares currently trade around $80.38.
Other Institutional Activity in Medtronic
BlackRock, Inc. reduced its holdings in Medtronic by 7.35 million shares, ending with 113.18 million shares valued at about $9.81 billion. Vanguard Capital Management LLC took a new position, acquiring 83.33 million shares worth approximately $7.22 billion. State Street Corp added 80,856 shares, bringing its total to 61.74 million shares valued at $5.39 billion. Meanwhile, JPMorgan Chase & Co cut its stake by 2.64 million shares, holding 50.97 million shares valued at $4.37 billion.
Medtronic plc Stock Down 13.1%
Medtronic shares are trading near $80.38. The company boasts a market capitalization of approximately $104.4 billion and a P/E ratio of 21.57. Its beta is relatively low at 0.597, indicating less volatility compared to the broader market. The stock's 52-week range spans from $73.31 to $106.33, with a 50-day moving average of $80.49 and a 200-day moving average of $92.06. Medtronic's debt-to-equity ratio stands at 57.06.
Recent Earnings
Medtronic reported revenue of $36.36 billion with a growth rate of 9.9%. The company achieved a net margin of 13.2% and a return on equity of 9.93%. The next earnings report is scheduled for August 18, 2026.
Dividend
Medtronic offers an annual dividend rate of $2.88, yielding 3.54%. The dividend payout ratio is 76.14%, reflecting the portion of earnings distributed as dividends.
Insider Buying and Selling at Medtronic plc
In early June 2026, several Medtronic insiders sold shares. CEO Geoffrey Martha sold 41,936 shares on June 4, while EVP Harry Skip Kiil sold 6,817 shares on the same day. EVP and President Cardiovascular, Harry Skip Kiil, also sold 4,189 shares on June 8. These transactions were not part of any planned sales.
Analysts Set New Price Targets
On June 17, 2026, Needham reiterated its buy rating with a $101 price target. Other analysts have also weighed in: Goldman Sachs maintained a hold rating with an $83 target on June 5, while Bernstein kept a buy rating with a $97 target. RBC Capital reiterated a buy rating with a $118 target on June 4.
About Medtronic
Medtronic plc is a leading medical device company based in Galway, Ireland. It develops and manufactures a wide range of device-based therapies for cardiovascular, neuroscience, medical-surgical, and diabetes care. Founded in 1949, the company employs around 95,000 people worldwide and is led by CEO Geoffrey Straub Martha.
Bottom Line
Needham's reaffirmation of its buy rating and $101 target for Medtronic signals continued confidence in the company's prospects. Investors often follow such analyst updates closely, though it's important to remember that these ratings are based on past performance and projections. As always, actual results may vary.
Get Medtronic plc alerts
New 13F filings, insider trades, and analyst moves on $MDT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.